


PHARMACEUTICAL 2017



BIOSPECIFICS TECHNOLOGIES CORP Rank 5 of 313





PHARMACEUTICAL 2017



BIOSPECIFICS TECHNOLOGIES CORP Rank 5 of 313

The relative strengths and weaknesses of BIOSPECIFICS TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOSPECIFICS TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 436% points. The greatest weakness of BIOSPECIFICS TECHNOLOGIES CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 345%, being 762% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	55,400
Cost of Goods Sold	0
Intangible Assets	258
Liabilities, Current	1,997
Liabilities, Non-Current	0
Other Assets	9,038
Other Compr. Net Income	0
Other Expenses	6,003
Other Liabilities	0
Other Net Income	349
Property and Equipment	0
Research and Development	1,328
Revenues	26,251
Selling, General and Administrative Expense	7,897

Output Variable	Value in 1000 USD
Assets	64,696
Liabilities	1,997
Expenses	15,227
Stockholders Equity	62,700
Net Income	11,372
Comprehensive Net Income	11,372
Economic Capital Ratio	345%